Ocular Therapeutix, Inc. Announces Closing Of Initial Public Offering

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today the closing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $13.00 per share, resulting in net proceeds of approximately $60.5 million after deducting underwriting discounts and commissions, and estimated offering expenses. All of the shares of common stock in the offering were sold by Ocular Therapeutix.

Help employers find you! Check out all the jobs and post your resume.